Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Clinical Trials

26 clinical trials for Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer — RECRUITING · PHASE1
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors — RECRUITING · PHASE1
• Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma — TERMINATED · PHASE2
• Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement — TERMINATED · PHASE2
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors — ACTIVE_NOT_RECRUITING
• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 — ACTIVE_NOT_RECRUITING · PHASE1
• Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families — ACTIVE_NOT_RECRUITING · NA
• VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
• Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma — COMPLETED · PHASE2
• Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma — COMPLETED · PHASE2
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies — TERMINATED · PHASE1
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors — ACTIVE_NOT_RECRUITING
• Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients — ACTIVE_NOT_RECRUITING · PHASE1
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma — TERMINATED · PHASE1
• Bone Loss in Melanoma Survivors Receiving Immunotherapy — TERMINATED
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies — TERMINATED · PHASE1
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma — TERMINATED · PHASE2
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma — TERMINATED · PHASE2
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer — COMPLETED · PHASE1
• CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma — TERMINATED · PHASE1

Refine this search